Substituted imidazoquinoxaline compounds and uses thereof
The disclosure provides substituted imidazo[1,5-a]quinoxaline and related compounds as kinase inhibitors, and their uses. Specifically, the disclosure provides compounds of Formula I, or pharmaceutically acceptable salts thereof or prodrugs thereof, wherein, A 1 -A 3 , Cy and R 1 -R 2 are defined herein. The compounds of Formula I are kinase inhibitors. Therefore, the compounds of the disclosure can be used to treat clinical conditions caused by DDR function defects, such as cancers.
1 . A compound of Formula I, or a stereoisomer, a tautomer, a N-oxide, a hydrate, an isotope-substituted derivative, a solvate thereof, or a pharmaceutically acceptable salt thereof, or a mixture thereof:
wherein A 1 is selected from the group consisting of N and CR 4 ; A 2 is selected from the group consisting of N and CR 5 ; A 3 is selected from the group consisting of N and CR 6 ;
Cy is selected from the group consisting of an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclic group, and an optionally substituted cycloalkyl;
R 1 is selected from the group consisting of an optionally substituted alkyl, an optionally substituted alkoxy, an optionally substituted amino, an optionally substituted carbocyclic group, an optionally substituted heterocyclic group, an optionally substituted aryl, and an optionally substituted heteroaryl;
R 2 is selected from the group consisting of an optionally substituted alkyl and an optionally substituted carbocyclic group; and
R 4 , R 5 , and R 6 are independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, alkenyl, alkynyl, amino, nitro, cyano, acylamino, acyloxy, hydroxy, sulfhydryl, alkylthio, azido, and carboxyl; wherein the alkyl, alkoxy, alkenyl, alkynyl, amino, acylamino, acyloxy, hydroxy, sulfhydryl, alkylthio, and carboxyl may be independently optionally substituted.
2 . The compound of claim 1 , or a stereoisomer, a tautomer, a N-oxide, a hydrate, an isotope-substituted derivative, a solvate thereof, or a pharmaceutically acceptable salt thereof, or a mixture thereof, wherein the compound of Formula I has the structure of Formula II:
wherein A 1 is selected from the group consisting of N and CR 4 ; A 2 is selected from the group consisting of N and CR 5 ; A 3 is selected from the group consisting of N and CR 6 ;
B 1 is selected from the group consisting of N and CR 7 ; B 2 is selected from the group consisting of N and CR 8 ; B 3 is selected from the group consisting of N and CR 9 ; and B 4 is selected from the group consisting of N and CR 10 ;
R 1 is selected from the group consisting of an optionally substituted alkyl, an optionally substituted alkoxy, an optionally substituted amino, an optionally substituted carbocyclic group, an optionally substituted heterocyclic group, an optionally substituted aryl, and an optionally substituted heteroaryl;
R 2 is selected from the group consisting of an optionally substituted alkyl and an optionally substituted carbocyclic group;
R 3 is selected from the group consisting of hydrogen, alkoxy, amino, carbocyclic group, heterocyclic group, aryl, and heteroaryl; wherein the alkoxy, amino, carbocyclic group, heterocyclic group, aryl, or heteroaryl may be independently optionally substituted; and
R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, alkenyl, alkynyl, amino, nitro, cyano, acylamino, acyloxy, hydroxy, sulfhydryl, alkylthio, azido, and carboxyl; wherein the alkyl, alkoxy, alkenyl, alkynyl, amino, acylamino, acyloxy, hydroxy, sulfhydryl, alkylthio, and carboxyl may be independently optionally substituted.
3 . The compound of claim 2 , or a stereoisomer, a tautomer, a N-oxide, a hydrate, an isotope-substituted derivative, a solvate thereof, or a pharmaceutically acceptable salt thereof, or a mixture thereof, wherein,
A 1 , A 2 , and A 3 are CR 4 , CR 5 , and CR 6 , respectively, wherein R 4 , R 5 , and R 6 are independently selected from the group consisting of hydrogen, halogen, C 1-4 alkyl, C 1-4 alkoxy, and halogenated C 1-4 alkyl;
the ring containing B 1 , B 2 , B 3 , and B 4 is selected from the group consisting of an optionally substituted pyridine ring and an optionally substituted phenyl ring;
R 1 is selected from the group consisting of an optionally substituted C 1-6 alkyl, heteroaryl group that is optionally substituted by 1-4 C 1-6 alkyls, and heterocyclic group that is optionally substituted by 1-4 C 1-6 alkyls;
R 2 is C 1-6 alkyl;
R 3 is selected from the group consisting of hydrogen, C 1-6 alkoxy that is optionally substituted by —NR 11 R 12 , —NR 11′ —C 1-6 alkyl-NR 11′ R 12′ , and heterocyclic group that is optionally substituted by —NR 11 R 12 , wherein, R 11′ and R 12′ are independently selected from the group consisting of H and C 1-4 alkyl or they together with the N atom they link to form a 4 to 8-membered heterocyclic group optionally substituted by 1-3 substituents selected from the group consisting of halogen, alkyl, and alkoxy, and R 11 and R 12 are independently selected from the group consisting of hydrogen and C 1-6 alkyl, or R 11 and R 12 together with the N atom they link to form a 4 to 8-membered heterocyclic group, which is optionally substituted by 1-3 substituents selected from the group consisting of halogen, alkyl, and alkoxy; and
R 7 , R 8 , R 9 , and R 10 are independently selected from the group consisting of hydrogen, halo, C 1-4 alkyl, and halogenated C 1-4 alkyl.
4 . The compound of claim 3 , or a stereoisomer, a tautomer, a N-oxide, a hydrate, an isotope-substituted derivative, a solvate thereof, or a pharmaceutically acceptable salt thereof, or a mixture thereof, wherein,
the ring containing B 1 B 2 , B 3 , and B 4 is a pyridine ring in which B 2 is N;
R 1 is selected from the group consisting of C 1-4 alkyl, tetrahydropyranyl that is optionally substituted by 1-4 C 1-6 alkyls, piperidinyl that is optionally substituted by 1-4 C 1-6 alkyls, morpholinyl that is optionally substituted by 1-4 C 1-6 alkyls, and piperazinyl that is optionally substituted by 1-4 C 1-6 alkyls; and
R 2 is methyl.
5 . The compound of claim 2 , wherein the compound is a compound of Formula IIIa or Formula IIIb, or a stereoisomer, a tautomer, a N-oxide, a hydrate, an isotope-substituted derivative, a solvate thereof, or a pharmaceutically acceptable salt thereof, or a mixture thereof:
wherein
R 6 is selected from the group consisting of hydrogen, halogen, alkyl, and alkoxy.
6 . The compound of claim 5 , or a stereoisomer, a tautomer, a N-oxide, a hydrate, an isotope-substituted derivative, a solvate thereof, or a pharmaceutically acceptable salt thereof, or a mixture thereof, wherein,
the ring containing B 1 , B 3 , and B 4 is an optionally substituted pyridine ring;
R 1 is selected from the group consisting of an optionally substituted C 1-6 alkyl, heteroaryl that is optionally substituted by 1-4 C 1-6 alkyls, and heterocyclic group that is optionally substituted by 1-4 C 1-6 alkyls;
R 2 is C 1-3 alkyl;
R 3 is selected from the group consisting of hydrogen, C 1-6 alkoxy that is optionally substituted by —NR 11 R 12 , —NR 11′ —C 1-6 alkyl-NR 11′ R 12′ , and heterocyclic group that is optionally substituted by —NR 11 R 12 , wherein R 11′ and R 12′ are independently selected from the group consisting of H and C 1-4 alkyl or they together with the N atom they link to form a 4 to 8-membered heterocyclic group optionally substituted by 1-3 substituents selected from the group consisting of halogen, alkyl, and alkoxy, and R 11 and R 12 are independently selected from hydrogen or C 1-6 alkyl, or R 11 and R 12 together with the N atom they link to form a 4 to 8-membered heterocyclic group, which is optionally substituted by 1-3 substituents selected from the group consisting of halogen, alkyl, and alkoxy;
R 6 is selected from the group consisting of hydrogen, halogen, C 1-4 alkyl, and C 1-4 alkoxy; and
R 7 , R 8 , R 9 , and R 10 are independently selected from the group consisting of hydrogen, C 1-4 alkoxy, halogen, C 1-4 alkyl, and halogenated C 1-4 alkyl.
7 . The compound of claim 6 , or a stereoisomer, a tautomer, a N-oxide, a hydrate, an isotope-substituted derivative, a solvate thereof, or a pharmaceutically acceptable salt thereof, or a mixture thereof, wherein,
R 1 is selected from the group consisting of C 1-4 alkyl, tetrahydropyranyl that is optionally substituted by 1-4 C 1-6 alkyls, piperidinyl that is optionally substituted by 1-4 C 1-6 alkyls, morpholinyl that is optionally substituted by 1-4 C 1-6 alkyls, and piperazinyl that is optionally substituted by 1-4 C 1-6 alkyls;
R 6 is hydrogen;
R 7 , R 9 , and R 10 are hydrogen; and
R 8 is selected from the group consisting of hydrogen, halogen, C 1-4 alkoxy, C 1-4 alkyl, and halogenated C 1-4 alkyl.
8 . The compound of claim 5 , or a stereoisomer, a tautomer, a N-oxide, a hydrate, an isotope-substituted derivative, a solvate thereof, or a pharmaceutically acceptable salt thereof, or a mixture thereof, wherein in Formulae IIIa and IIIb:
R 1 is a heterocyclic group optionally substituted by 1-2 substituents selected from the group consisting of C 1-6 alkyl;
R 2 is C 1-4 alkyl;
R 3 is a C 1-6 alkoxy optionally substituted by —NR 11 R 12 , or a heterocyclic group optionally substituted by —NR 11 R 12 , wherein R 11 and R 12 are independently selected from hydrogen or C 1-6 alkyl or R 11 and R 12 together with the N atom they link to form a 4 to 8-membered heterocyclic group optionally substituted by 1-2 alkyls;
R 6 is selected from the group consisting of hydrogen, halogen, and C 1-4 alkoxy; and
in Formula IIIa, B 1 , B 3 , and B 4 are CH;
in Formula IIIb, R 7 , R 9 , and R 10 are H.
9 . The compound of claim 8 , or a stereoisomer, a tautomer, a N-oxide, a hydrate, an isotope-substituted derivative, a solvate thereof, or a pharmaceutically acceptable salt thereof, or a mixture thereof, wherein in Formulae IIIa and IIIb:
R 1 is morpholinyl optionally substituted by 1-2 C 1-6 alkyls;
R 2 is methyl;
the heterocyclic group optionally substituted by —NR 11 R 12 in R 3 is a piperidinyl or a piperazinyl with their ring nitrogen atom linking to the rest of the compound, which is optionally substituted by the —NR 11 R 12 group;
R 6 is hydrogen; and
in Formula IIIa, B 1 , B 3 , and B 4 are CH;
in Formula IIIb, R 7 , R 9 , and R 10 are H.
10 . The compound of claim 5 , or a stereoisomer, a tautomer, a N-oxide, a hydrate, an isotope-substituted derivative, a solvate thereof, or a pharmaceutically acceptable salt thereof, or a mixture thereof, wherein in Formula IIIb:
R 1 is selected from the group consisting of a C 1-6 alkyl, a heteroaryl optionally substituted by 1-3 substituents selected from the group consisting of halogen, C 1-4 alkyl, and C 1-4 alkoxy, and a heterocyclic group optionally substituted by 1-2 substituents selected from the group consisting of C 1-6 alkyl;
R 2 is C 1-6 alkyl;
R 3 is C 1-6 alkoxy optionally substituted by —NR 11 R 12 , —NR 11′ —C 1-6 alkyl-NR 11′ R 12′ , or heterocyclic group optionally substituted by —NR 11 R 12 , wherein R 11′ and R 12′ are independently selected from the group consisting of H and C 1-4 alkyl, R 11 and R 12 are independently selected from hydrogen or C 1-6 alkyl or R 1 and R 12 together with the N atom they link to form a 4 to 8-membered heterocyclic group optionally substituted by 1-2 alkyls;
R 6 is selected from the group consisting of hydrogen, halogen, and C 1-4 alkoxy;
R 7 , R 9 , and R 10 are H; and
R 8 is selected from the group consisting of H, halogen, C 1-4 alkyl substituted by 1-4 halogen, and C 1-4 alkoxy.
11 . The compound of claim 5 , or a stereoisomer, a tautomer, a N-oxide, a hydrate, an isotope-substituted derivative, a solvate thereof, or a pharmaceutically acceptable salt thereof, or a mixture thereof, wherein:
R 1 is selected from the group consisting of:
R 2 is C 1-3 alkyl;
R 3 is selected from the group consisting of:
12 . The compound of claim 5 , or a stereoisomer, a tautomer, a N-oxide, a hydrate, an isotope-substituted derivative, a solvate thereof, or a pharmaceutically acceptable salt thereof, or a mixture thereof, wherein in Formula IIIb:
R 1 is selected from the group consisting of C 1-4 alkyl, tetrahydropyranyl optionally substituted by 1-2 C 1-6 alkyls, piperidinyl optionally substituted by 1-2 C 1-6 alkyls, morpholinyl optionally substituted by 1-2 C 1-6 alkyls, pyridyl optionally substituted by 1-2 substituents selected from the group consisting of halogen and C 1-4 alkoxy, and piperazinyl optionally substituted by 1-3 C 1-6 alkyls;
R 2 is C 1-4 alkyl;
R 3 is a piperidinyl or a piperazinyl with their ring nitrogen atom linking to the rest of the compound, and R 3 is optionally substituted by a —NR 11 R 12 group, wherein R 11 and R 12 are independently selected from hydrogen or C 1-6 alkyl or R 11 and R 12 together with the N atom they link to form a 4 to 8-membered heterocyclic group optionally substituted by 1-2 alkyls.
13 . A compound of claim 1 , wherein the compound is selected from the group consisting of:
N,N-dimethyl-3-((5-(3-methyl-1-(tetrahydro-2H-pyran-4-yl)imidazo[1,5-a]quinoxalin-8-yl)pyridin-2-yl)oxy)propan-1-amine;
N,N-dimethyl-3-(4-(3-methyl-1-(tetrahydro-2H-pyran-4-yl)imidazo[1,5-a]quinoxalin-8-yl)phenoxy)propan-1-amine;
N,N-dimethyl-3-(2-fluoro-4-(3-methyl-1-(tetrahydro-2H-pyran-4-yl)imidazo[1,5-a]quinoxalin-8-yl)phenoxy)propan-1-amine;
N,N-dimethyl-3-(4-(3-methyl-1-(tetrahydro-2H-pyran-4-yl)imidazo[1,5-a]quinoxalin-8-yl)-2-(trifluoromethyl)phenoxy)propan-1-amine;
N,N-dimethyl-1-(2-fluoro-4-(3-methyl-1-(tetrahydro-2H-pyran-4-yl)imidazo[1,5-a]quinoxalin-8-yl)phenyl)piperidin-4-amine;
N,N-dimethyl-1-(2-chloro-4-(3-methyl-1-(tetrahydro-2H-pyran-4-yl)imidazo[1,5-a]quinoxalin-8-yl)phenyl)piperidin-4-amine;
N,N-dimethyl-1-(4-(3-methyl-1-(tetrahydro-2H-pyran-4-yl)imidazo[1,5-a]quinoxalin-8-yl)-2-(trifluoromethyl)phenyl)piperidin-1-amine;
1-(4-(3-methyl-1-(tetrahydro-2H-pyran-4-yl)imidazo[1,5-a]quinoxalin-8-yl)-2-(trifluoromethyl)phenyl)piperidin-4-amine;
N-methyl-1-(4-(3-methyl-1-(tetrahydro-2H-pyran-4-yl)imidazo[1,5-a]quinoxalin-8-yl)-2-(trifluoromethyl)phenyl)piperidin-4-amine;
N-ethyl-1-(4-(3-methyl-1-(tetrahydro-2H-pyran-4-yl)imidazo[1,5-a]quinoxalin-8-yl)-2-(trifluoromethyl)phenyl)piperidin-4-amine;
3-methyl-8-(6-(3-(piperidin-yl)propoxy)pyridin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)imidazo[1,5-a]quinoxaline;
8-(1,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1-(tetrahydro-2H-pyran-4-yl)imidazo[1,5-a]quinoxaline;
N,N-dimethyl-3-((5-(3-methyl-1-morpholinylimidazo[1,5-a]quinoxalin-8-yl)pyridin-2-yl)oxy)propan-1-amine;
N,N-dimethyl-3-((5-(1-((2S,6R)-2,6-dimethylmorpholino)-3-methylimidazo[1,5-a]quinoxalin-8-yl)pyridin-2-yl)oxy)propan-1-amine;
N,N-dimethyl-3-((5-(3-methyl-1-(piperidin-1-yl)imidazo[1,5-a]quinoxalin-8-yl)pyridin-2-yl)oxy)propan-1-amine;
N,N-dimethyl-3-((5-(3-methyl-1-(4-methylpiperazin-1-yl)imidazo[1,5-a]quinoxalin-8-yl)pyridin-2-yl)oxy)propan-1-amine;
N,N-dimethyl-3-((5-(3-methyl-1-((3S,5R)-3,4,5-trimethylpiperazin-1-yl)imidazo[1,5-a]quinoxalin-8-yl)pyridin-2-yl)oxy)propan-1-amine;
N,N-dimethyl-3-((5-(1-isopropyl-3-methylimidazo[1,5-a]quinoxalin-8-yl)pyridin-2-yl)oxy)propan-1-amine;
N,N-dimethyl-3-(2-fluoro-4-(1-isopropyl-3-methylimidazo[1,5-a]quinoxalin-8-yl)phenoxy)propan-1-amine;
N,N-dimethyl-3-(4-(1-isopropyl-3-methylimidazo[1,5-a]quinoxalin-8-yl)-2-(trifluoromethyl)phenoxy)propan-1-amine;
1-isopropyl-3-methyl-8-(6-(3-(piperidin-1-yl)propoxy)pyridin-3-yl)imidazo[1,5-a]quinoxaline;
7-fluoro-1-isopropyl-3-methyl-8-(6-(3-(piperidin-1-yl)propoxy)pyridin-3yl)imidazo[1,5-a]quinoxaline;
N,N-dimethyl-1-(2-fluoro-4-(1-isopropyl-3-methylimidazo[1,5-a]quinoxalin-8-yl)phenyl)piperidin-4-amine;
N,N-dimethyl-1-(2-chloro-4-(1-isopropyl-3-methylimidazo[1,5-a]quinoxalin-8-yl)phenyl)piperidin-4-amine;
N,N-dimethyl-1-(4-(1-isopropyl-3-methylimidazo[1,5-a]quinoxalin-8-yl)-2-(trifluoromethyl)phenyl)piperidin-4-amine;
1-(4-(1-isopropyl-3-methylimidazo[1,5-a]quinoxalin-8-yl)-2-(trifluoromethyl)phenyl)piperidin-4-amine;
N-methyl-1-(4-(1-isopropyl-3-methylimidazo[1,5-a]quinoxalin-8-yl)-2-(trifluoromethyl)phenyl)piperidin-4-amine;
N-ethyl-1-(4-(1-isopropyl-3-methylimidazo[1,5-a]quinoxalin-8-yl)-2-(trifluoromethyl)phenyl)piperidin-4-amine;
8-(1,3-dimethyl-4H-1λ 4 -pyrazol-4-yl)-1-(3-fluoro-5-methoxypyridin-4-yl)-7-methoxy-3-methylimidazo[1,5-a]quinoxaline;
(2S,6R)-4-(8-(6-(3-(azetidin-1-yl)propoxy)pyridin-3-yl)-3-methylimidazo[1,5-a]quinoxalin-1-yl)-2,6-dimethylmorpholine;
(2S,6R)-2,6-dimethyl-4-(3-methyl-8-(6-(3-(pyrrolidin-1-yl)propoxy)pyridin-3-yl)imidazo[1,5-a]quinoxalin-1-yl)morpholine;
(2S,6R)-2,6-dimethyl-4-(3-methyl-8-(6-(3-(piperidin-1-yl)propoxy)pyridin-3-yl)imidazo[1,5-a]quinoxalin-1-yl)morpholine;
(2S,6R)-4-(8-(6-(2-(1H-imidazol-2-yl)ethoxy)pyridin-3-yl)-3-methylimidazo[1,5-a]quinoxalin-1-yl)-2,6-dimethylmorpholine;
(2S,6R)-4-(8-(6-(2-(1H-imidazol-4-yl)ethoxy)pyridin-3-yl)-3-methylimidazo[1,5-a]quinoxalin-1-yl)-2,6-dimethylmorpholine;
2-((5-(1-((2S,6R)-2,6-dimethylmorpholino)-3-methylimidazo[1,5-a]quinoxalin-8-yl)pyridin-2-yl)oxy)-N,N-dimethylethan-1-amine;
3-((4-(1-((2S,6R)-2,6-dimethylmorpholino)-3-methylimidazo[1,5-a]quinoxalin-8-yl)-2-(trifluoromethyl)phenoxy)-N,N-dimethylpropan-1-amine;
1-(5-(1-((2S,6R)-2,6-dimethylmorpholino)-3-methylimidazo[1,5-a]quinoxalin-8-yl)pyridin-2-yl)-N,N-dimethylpiperidin-4-amine;
1-(4-(1-((2S,6R)-2,6-dimethylmorpholino)-3-methylimidazo[1,5-a]quinoxalin-8-yl)-2-fluorophenyl)-N,N-dimethylpiperidin-4-amine;
1-(2-chloro-4-(1-((2S,6R)-2,6-dimethylmorpholino)-3-methylimidazo[1,5-a]quinoxalin-8-yl)phenyl)-N,N-dimethylpiperidin-4-amine;
3-((5-(1-((2S,6R)-2,6-dimethylmorpholino)-3-ethylimidazo[1,5-a]quinoxalin-8-yl)pyridin-2-yl)oxy)-N,N-dimethylpropan-1-amine;
3-((5-(1-((2S,6R)-2,6-dimethylmorpholino)-3-isopropylimidazo[1,5-a]quinoxalin-8-yl)pyridin-2-yl)oxy)-N,N-dimethylpropan-1-amine;
3-((5-(1-((2S,6R)-2,6-dimethylmorpholino)imidazo[1,5-a]quinoxalin-8-yl)pyridin-2-yl)oxy)-N,N-dimethylpropan-1-amine;
N,N-dimethyl-3-((5-(1-((3S,5R)-3,4,5-trimethylpiperazin-1-yl)imidazo[1,5-a]quinoxalin-8-yl)pyridin-2-yl)oxy)propan-1-amine;
1-(5-(1-((2S,6R)-2,6-dimethylmorpholino)imidazo[1,5-a]quinoxalin-8-yl)pyridin-2-yl)-N,N-dimethylpiperidin-4-amine;
N 1 -(5-(1-((2S,6R)-2,6-dimethylmorpholino)-3-methylimidazo[1,5-a]quinoxalin-8-yl)pyridin-2-yl)-N 3 ,N 3 -dimethylpropane-1,3-diamine;
N 1 -(5-(1-((2S,6R)-2,6-dimethylmorpholino)-3-methylimidazo[1,5-a]quinoxalin-8-yl)pyridin-2-yl)-N 1 ,N 3 ,N 3 -trimethylpropane-1,3-diamine;
1-(5-(1-((2S,6R)-2,6-dimethylmorpholino)-3-methylimidazo[1,5-a]quinoxalin-8-yl)pyridin-2-yl)piperidin-4-amine;
1-(5-(1-((2S,6R)-2,6-dimethylmorpholino)-3-methylimidazo[1,5-a]quinoxalin-8-yl)pyridin-2-yl)-N-methylpiperidin-4-amine;
1-(5-(1-((2S,6R)-2,6-dimethylmorpholino)-3-methylimidazo[1,5-a]quinoxalin-8-yl)pyridin-2-yl)-N-ethylpiperidin-4-amine;
1-(5-(1-((2S,6R)-2,6-dimethylmorpholino)-3-methylimidazo[1,5-a]quinoxalin-8-yl)pyridin-2-yl)-N-isopropylpiperidin-4-amine;
(2S,6R)-4-(8-(6-(4-(azetidin-1-yl)piperidin-1-yl)pyridin-3-yl)-3-methylimidazo[1,5-a]quinoxalin-1-yl)-2,6-dimethylmorpholine;
3-((5-(1-((2S,6R)-2,6-dimethylmorpholino)-3-methylimidazo[1,5-a]quinoxalin-8-yl)pyridin-2-yl)oxy)propan-1-amine;
3-((5-(1-((2S,6R)-2,6-dimethylmorpholino)-3-methylimidazo[1,5-a]quinoxalin-8-yl)pyridin-2-yl)oxy)-N-methylpropan-1-amine;
3-((5-(1-((2S,6R)-2,6-dimethylmorpholino)-3-methylimidazo[1,5-a]quinoxalin-8-yl)pyridin-2-yl)oxy)-N-ethylpropan-1-amine;
3-((5-(1-((2S,6R)-2,6-dimethylmorpholino)-3-methylimidazo[1,5-a]quinoxalin-8-yl)pyridin-2-yl)oxy)-N-ethyl-N-methylpropan-1-amine;
3-((5-(1-((2S,6R)-2,6-dimethylmorpholino)-3-methylimidazo[1,5-a]quinoxalin-8-yl)pyridin-2-yl)oxy)-N,N-diethylpropan-1-amine;
(2S,6R)-2,6-dimethyl-4-(3-methyl-8-(6-(3-morpholinopropoxy)pyridin-3-yl)imidazo[1,5-a]quinoxalin-1-yl)morpholine;
(2S,6R)-2,6-dimethyl-4-(3-methyl-8-(6-(3-(4-methylpiperazin-1-yl)propoxy)pyridin-3-yl)imidazo[1,5-a]quinoxalin-1-yl)morpholine;
(2S,6R)-2,6-dimethyl-4-(3-methyl-8-(6-(2-(4-methylpiperazin-1-yl)ethyl)pyridin-3-yl)imidazo[1,5-a]quinoxalin-1-yl)morpholine;
3-(4-(1-((2S,6R)-2,6-dimethylmorpholino)-3-methylimidazo[1,5-a]quinoxalin-8-yl)-2-fluorophenoxy)-N,N-dimethylpropan-1-amine;
3-(2-chloro-4-(1-((2S,6R)-2,6-dimethylmorpholino)-3-methylimidazo[1,5-a]quinoxalin-8-yl)phenoxy)-N,N-dimethylpropan-1-amine;
1-(5-(1-((2R,6R)-2,6-dimethylmorpholino)-3-methylimidazo[1,5-a]quinoxalin-8-yl)pyridin-2-yl)-N,N-dimethylpiperidin-4-amine and 1-(5-(1-((2S,6S)-2,6-dimethylmorpholino)-3-methylimidazo[1,5-a]quinoxalin-8-yl)pyridin-2-yl)-N,N-dimethylpiperidin-4-amine;
3-((5-(1-((2R,6R)-2,6-dimethylmorpholino)-3-methylimidazo[1,5-a]quinoxalin-8-yl)pyridin-2-yl)oxy)-N,N-dimethylpropan-1-amine and 3-((5-(1-((2S,6S)-2,6-dimethylmorpholino)-3-methylimidazo[1,5-a]quinoxalin-8-yl)pyridin-2-yl)oxy)-N,N-dimethylpropan-1-amine;
or a stereoisomer, a tautomer, a N-oxide, a hydrate, an isotope-substituted derivative, a solvate thereof, or a pharmaceutically acceptable salt thereof, or a mixture thereof.
14 . A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
15 . The pharmaceutical composition of claim 14 , wherein the composition further comprises at least one known anticancer agent or a pharmaceutically acceptable salt of the anticancer agent.
16 . The pharmaceutical composition of claim 15 , wherein the composition further comprises at least one anticancer agent selected from the group consisting of busulfan, melphalan, chlorambucil, cyclophosphamide, ifosfamide, temozolomide, bendamustine, cis-platin, mitomycin C, bleomycin, carboplatin, camptothecin, irinotecan, topotecan, doxorubicin, epirubicin, aclarubicin, mitoxantrone, methylhydroxy ellipticine, etoposide, 5-azacytidine, gemcitabine, 5-fluorouracil, methotrexate, 5-fluoro-2′-deoxy-uridine, fludarabine, nelarabine, ara-C, alanosine, pralatrexate, pemetrexed, hydroxyurea, thioguanine, colchicine, vinblastine, vincristine, vinorelbine, paclitaxel, ixabepilone, cabazitaxel, docetaxel, mAb, panitumumab, Ofatumumab, avastin, herceptin, mabthera, imatinib, gefitinib, erlotinib, lapatinib, sorafenib, sunitinib, nilotinib, dasatinib, pazopanib, torisel, everolimus, vorinostat, romidepsin, tamoxifen, letrozole, fulvestrant, mitoguazone, octreotide, retinoic acid, arsenic trioxide, zoledronic acid, bortezomib, thalidomide, lenalidomide, Venetoclax, Aldesleukin, Sipueucel-T, Palbociclib, Olaparib, Niraparib, Rucaparib, Talazoparib, and Senaparib.
17 . A method for treating or preventing a disease caused by a DDR function defect or a disease that benefits from inhibition of kinase activity in a subject in need thereof, comprising administering to the subject an effective amount of a compound or a stereoisomer, a tautomer, a N-oxide, a hydrate, an isotope-substituted derivative, a solvate or a pharmaceutically acceptable salt thereof, or a mixture thereof of claim 1 , or a pharmaceutical composition comprising the compound or a stereoisomer, a tautomer, a N-oxide, a hydrate, an isotope-substituted derivative, a solvate, or a pharmaceutically acceptable salt thereof, or a mixture thereof, and a pharmaceutically acceptable carrier.
18 . The method of claim 17 , wherein the disease is a cancer.
19 . The method of claim 18 , wherein the cancer is selected from the group consisting of liver cancer, melanoma, Hodgkin's disease, non-Hodgkin's lymphoma, acute lymphocytic leukemia, chronic lymphocytic leukemia, multiple myeloma, neuroblastoma, breast cancer, ovarian cancer, lung cancer, Wilms tumor, cervical cancer, testicular cancer, soft tissue sarcoma, chronic lymphocytic leukemia, primary macroglobulinemia, bladder cancer, chronic myeloid leukemia, primary brain cancer, malignant melanoma, small cell lung cancer, gastric cancer, colon cancer, malignant pancreatic islet tumor, malignant carcinoid cancer, malignant melanoma, choriocarcinoma, mycosis fungoides, head and neck cancer, osteogenic sarcoma, pancreatic cancer, acute myeloid leukemia, hairy cell leukemia, rhabdomyosarcoma, Kaposi's sarcoma, urogenital tumors, thyroid cancer, esophageal cancer, malignant hypercalcemia, cervical hyperplasia, renal cell carcinoma, endometrial cancer, polycythemia vera, idiopathic thrombocythemia, adrenocortical carcinoma, skin cancer, prostate cancer, and Huntington's disease.
20 . The method of claim 19 , further comprising administering to the subject at least one known anticancer agent or a pharmaceutically acceptable salt of the anticancer agent; or wherein the subjected is treated in combination with radiotherapy.
21 . The method of claim 20 , wherein the at least one anticancer agent is selected from the group consisting of busulfan, melphalan, chlorambucil, cyclophosphamide, ifosfamide, temozolomide, bendamustine, cis-platin, mitomycin C, bleomycin, carboplatin, camptothecin, irinotecan, topotecan, doxorubicin, epirubicin, aclarubicin, mitoxantrone, methylhydroxy ellipticine, etoposide, 5-azacytidine, gemcitabine, 5-fluorouracil, methotrexate, 5-fluoro-2′-deoxy-uridine, fludarabine, nelarabine, ara-C, alanosine, pralatrexate, pemetrexed, hydroxyurea, thioguanine, colchicine, vinblastine, vincristine, vinorelbine, paclitaxel, ixabepilone, cabazitaxel, docetaxel, mAb, panitumumab, Ofatumumab, avastin, herceptin, mabthera, imatinib, gefitinib, erlotinib, lapatinib, sorafenib, sunitinib, nilotinib, dasatinib, pazopanib, torisel, everolimus, vorinostat, romidepsin, tamoxifen, letrozole, fulvestrant, mitoguazone, octreotide, retinoic acid, arsenic trioxide, zoledronic acid, bortezomib, thalidomide, lenalidomide, Venetoclax, Aldesleukin, Sipueucel-T, Palbociclib, Olaparib, Niraparib, Rucaparib, Talazoparib, and Senaparib.